Targeted Technology is a venture capital firm established in 2009 and located in San Antonio, Texas. The firm focuses on early-stage investments in startups that are developing medical devices, biotechnology, life science tools, diagnostics, specialty pharmaceuticals, and personalized medicine. Targeted Technology aims to identify companies with groundbreaking or disruptive technologies that can enhance medical practices and improve patient outcomes. Additionally, the firm seeks innovations that can increase efficiency, reduce costs, or enhance the functionality of life science product development and manufacturing. Its investment preference is primarily directed towards companies based in the Southeastern and Southwestern United States, including regions such as Texas, Birmingham, Alabama, Georgia, Alamo City, and San Antonio.
Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.
Roxy’s Remedies
Series A in 2016
Roxy’s Remedies provides natural grooming products for dogs with canine atopic dermatitis. Roxy’s Remedies' product line is formulated with sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO) produced by TFS Corporation Ltd. EISO is a natural, calming ingredient that has been used as a traditional skin healing agent and is being developed by Santalis as a prescription drug for human skin conditions.
StemBioSys
Series A in 2015
StemBioSys manufactures and develops novel, proprietary stem cell technologies to meet the promise of regenerative medicine in a surging global market. Housed in San Antonio, StemBioSys is led by an experienced management and scientific team.
Xenex
Venture Round in 2015
Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections. The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load often associated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S. Xenex was founded in 2009 and headquartered in San Antonio, Texas.
DNAtrix
Series B in 2014
DNAtrix, Inc. is a clinical-stage biotechnology company based in Texas that specializes in developing virus-driven immunotherapies for cancer treatment. The company’s leading product, DNX-2401, is an oncolytic immunotherapy designed to target and kill glioblastoma cells, a particularly aggressive form of brain cancer. This therapy has shown promising early results, with over 35 patients treated. DNAtrix is also developing additional armed DNX viruses, specifically DNX-2440 and DNX-2450, aimed at treating various solid tumors, as well as MYX-135, which targets hematological malignancies. With a focus on harnessing modified viruses to selectively destroy cancer cells while stimulating the immune system, DNAtrix seeks to expand its platform to address other cancers, including brain metastases, ovarian, and pancreatic cancers. The company was incorporated in 2005 and maintains its headquarters in Houston, Texas, with an additional office in San Diego, California.
Bluegrass Vascular Technologies
Series A in 2014
Bluegrass Vascular Technologies, Inc. is a medical technology company focused on developing and commercializing innovative devices to improve vascular access procedures for patients with obstructed central venous systems. The company's flagship product, the Surfacer Inside-Out Access Catheter System, allows physicians to achieve central venous access by inserting a guide wire through the femoral vein and guiding it to exit at either the jugular or subclavian vein. This system is designed to enhance patient safety and reduce complications during vascular access procedures. Founded in 2010 and headquartered in San Antonio, Texas, Bluegrass Vascular Technologies serves patients both in the United States and internationally.
Xenex
Venture Round in 2013
Xenex is offering an effective approach to reducing the incidence of healthcare-associated infections. The Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital-acquired infections (HAIs). Xenex’s Pulsed Xenon Full Spectrum™ UV Disinfection Solution reduces the bacterial load often associated with an increased risk for HAIs. Since its commercial launch in June 2010, Xenex devices are now included in infection control protocols in almost three hundred hospitals throughout the U.S. Xenex was founded in 2009 and headquartered in San Antonio, Texas.
ViroXis
Private Equity Round in 2013
ViroXis is a bio-pharmaceutical company focused on developing and commercializing innovative, properietary, botanical pharmaceuticals derived from Sandalwood Oil. The hardwood oils of the East Indian and West Australian sandalwood trees, S.album and S. spicatum, have a long and extensive history of traditional use for a variety of conditions, including the successful treatment of various skin disorders, including skin viral and difficult-to-treat microbial infections.
Bi02 Medical
Series C in 2012
Bi02 Medical, Inc. specializes in the design, development, manufacture, and commercialization of medical devices aimed at addressing clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter designed to protect against prophylactic pulmonary embolism and facilitate access to the central venous system in critically ill patients. This device allows for the administration of medications, fluids, and blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical's products are distributed globally through various partners. Founded in 2006, the company is headquartered in San Antonio, Texas, and operates a research and development and manufacturing facility in Golden, Colorado.
Bi02 Medical
Series B in 2012
Bi02 Medical, Inc. specializes in the design, development, manufacture, and commercialization of medical devices aimed at addressing clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter designed to protect against prophylactic pulmonary embolism and facilitate access to the central venous system in critically ill patients. This device allows for the administration of medications, fluids, and blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical's products are distributed globally through various partners. Founded in 2006, the company is headquartered in San Antonio, Texas, and operates a research and development and manufacturing facility in Golden, Colorado.
VidaCare
Venture Round in 2009
Vidacare Corporation, a medical device company, engages in the development, manufacture, and marketing of intraosseous access devices for diagnostic, monitoring, and therapeutic applications. The company provides EZ-IO Product System, which is designed to provide controlled vascular access through the intraosseous route to patients in emergent situations when vascular access is challenging and impossible. It also offers EZ-IO power driver, which is designed to penetrate the intraosseous space by drilling through the bone with a hollow needle and integrated stylet that doubles as the forward cutting bit to secure its correct placement; and EZ-IO Vascular Access Pack, a kit developed for emergency medical specialists to provide access to IV and IO devices to gain vascular access. In addition, the company provides a suite of hematology/oncology products, including a power driver and needle sets for bone marrow aspiration and biopsy; and OnControl, a bone marrow system for clinicians to perform bone marrow aspiration and biopsy procedures. Its products are used in pre-hospital, emergency, crash cart, and rapid response applications, as well as in military and homeland security industries. Vidacare Corporation was founded in 2001 and is headquartered in San Antonio, Texas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.